caa a22 4500 465789625 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00171849 doi (NATIONALLICENCE)springer-10.1007/BF00171849 Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma [Elektronische Daten] Results of an Eastern Cooperative Oncology Group study (EST 2685) [Howard Hochster, Myla Hunt, Michael Green, David Parkinson, Thomas Smith] Summary: In this phase II trial, twenty patients with advanced, measurable melanoma from ECOG institutions were treated with esorubicin 30 mg/m2 iv every three weeks. Doses were escalated or reduced based on nadir counts. The dose limiting toxicity was leukopenia with no significant thrombocytopenia or anemia. Other toxicities were mild. One patient had skin necrosis with extravasation. Two patients with soft tissue disease had partial remissions and were treated with 9 and 17 courses. One patient was stable for 8 courses. No cardiac toxicity was seen in three patients receiving more than 150 mg/m2. The response rate was 10% (90% CI = 2 to 30%). Low level activity was seen, but it is unlikely that this drug has sufficient activity to warrant further development in melanoma. Kluwer Academic Publishers, 1990 esorubicin nationallicence deoxydoxorubicin nationallicence melanoma nationallicence clinical nationallicence Hochster Howard New York University Medical Center, 16395, New York, CA, USA aut Hunt Myla Dana-Farber Cancer Institute, Harvard School of Public Health, (CA 23318), Boston, MA aut Green Michael New York University Medical Center, 16395, New York, CA, USA aut Parkinson David New York University Medical Center, 530 First Avenue, 10016, New York, NY, USA aut Smith Thomas New York University Medical Center, 530 First Avenue, 10016, New York, NY, USA aut Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 329-332 0167-6997 8:3<329 1990 8 10637 https://doi.org/10.1007/BF00171849 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171849 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hochster Howard New York University Medical Center, 16395, New York, CA, USA aut NATIONALLICENCE 700 1- Hunt Myla Dana-Farber Cancer Institute, Harvard School of Public Health, (CA 23318), Boston, MA aut NATIONALLICENCE 700 1- Green Michael New York University Medical Center, 16395, New York, CA, USA aut NATIONALLICENCE 700 1- Parkinson David New York University Medical Center, 530 First Avenue, 10016, New York, NY, USA aut NATIONALLICENCE 700 1- Smith Thomas New York University Medical Center, 530 First Avenue, 10016, New York, NY, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 329-332 0167-6997 8:3<329 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer